克拉屈滨-成人朗格汉斯综合征EPI14070709.pdf

Pediatr Blood Cancer 2013;60:E19–E22 BRIEF REPORT Clofarabine Salvage Therapy for Refractory High-Risk Langerhans Cell Histiocytosis Allistair Abraham, MD,1 Abdulrahman Alsultan, MD,2 Michael Jeng, MD,3 Carlos Rodriguez-Galindo, MD,4 and Patrick K. Campbell, MD, PhD1* Pediatric patients with refractory multisystem Langerhans cell clofarabine with minimal toxicity. In this report, we describe four histiocytosis (LCH) have a poor prognosis despite aggressive children with refractory, risk-organ-positive LCH who were treated chemotherapy. Salvage therapy with cytarabine and cladribine has with clofarabine and provide follow-up for the two previously shown promise as an effective treatment but is associated with reported cases. The results support development of a formal trial significant toxicity. A previous report described two patients with evaluating clofarabine as front-line salvage for refractory LCH.Pediatr refractory LCH who had a rapid response to single-agent Blood Cancer 2013;60:E19–E22. 2012 Wiley Periodicals, Inc. Key words: clofarabine; Langerhans cell histiocytosis INTRODUCTION and vinblastine. Initial chemotherapy for Patient 6 was influenced by treatment for pre-existing T-cell acute lymphoblastic leukemia Langerhans cell histiocytosis (LCH) is a clonal, proliferative (ALL). Patient 1 developed vocal cord paralysis after 2 weeks of disorder of immature dendritic cells ranging fr